Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · INOVIO PHARMACEUTICALS, INC. (INO)

Inovio expects about $80.5 million net proceeds from stock offering

Mixed Impact 4 of 5 financing

On November 5, 2026, Inovio agreed to sell 58,747,235 common shares at $1.05 each and pre-funded warrants for 12,681,337 shares at $1.049 each, and on November 6 the underwriters exercised their option to buy 10,714,285 more shares in full. Net proceeds are expected to be about $80.5 million, with closing expected on or about November 9, 2026. The sale adds to the shares outstanding, which dilutes existing holders, but the company says the proceeds and current cash will fund operations into late fourth quarter 2027.

Key points

  • 58,747,235 common shares sold at $1.05 per share, plus pre-funded warrants for 12,681,337 shares at $1.049 each
  • Underwriters exercised their option for 10,714,285 additional shares in full on November 6, 2026
  • Net proceeds expected to be about $80.5 million; closing expected on or about November 9, 2026
  • Company believes proceeds and current cash will fund operations into late fourth quarter 2027

The filing

CompanyINOVIO PHARMACEUTICALS, INC. (INO)
Form8-K, current report
Filed with the SECNov 9, 2026, 7:30 AM ET
Accession number0001193125-26-452658

Items reported: 1.01 Material Definitive Agreement7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 7:35 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.